CTI BioPharma (CTI BioPharma) Dividend Payout Ratio : 0.00 (As of Mar. 2023)

View and export this data going back to 1997. Start your Free Trial

What is CTI BioPharma Dividend Payout Ratio?

CTI BioPharma's dividend payout ratio for the months ended in Mar. 2023 was 0.00.

The historical rank and industry rank for CTI BioPharma's Dividend Payout Ratio or its related term are showing as below:

CTIC's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.415
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-26), the Dividend Yield % of CTI BioPharma is 0.00%.

CTI BioPharma's Dividends per Share for the months ended in Mar. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

CTI BioPharma Dividend Payout Ratio Historical Data

The historical data trend for CTI BioPharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Dividend Payout Ratio Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividend Payout Ratio

Get a 7-Day Free Trial

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CTI BioPharma's Dividend Payout Ratio

For the Biotechnology subindustry, CTI BioPharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CTI BioPharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Dividend Payout Ratio falls into.

CTI BioPharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

CTI BioPharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-0.81
	=	N/A

CTI BioPharma's Dividend Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2023 )	/	EPS without NRI (Q: Mar. 2023 )
	=	0	/	-0.1
	=	N/A

CTI BioPharma (NAS:CTIC) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

CTI BioPharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (CTI BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (NAS:CTIC) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

Executives

James K Fong	officer: EVP & Chief Commercial Officer	C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121
Adam R Craig	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
David Kirske	officer: EVP, Chief Financial Officer	C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Matthew D Perry	director	ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Laurent Fischer	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
David Ross Parkinson	director	C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Richard L Love	director
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104